Surface Oncology
United States
111 articles about Surface Oncology
-
Coherus Completes Surface Oncology Acquisition
9/8/2023
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the closing of the previously announced acquisition of Surface Oncology, Inc.
-
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
8/31/2023
Surface Oncology, Inc. announced that both Institutional Shareholder Services and Glass, Lewis & Co. have recommended Surface stockholders vote “FOR” the adoption of Surface’s merger agreement with Coherus BioSciences, Inc.
-
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
8/2/2023
Surface Oncology today reported financial results and corporate highlights for the second quarter 2023.
-
The stock deal aims to strengthen Coherus Biosciences’ position in the field of cancer therapeutics and expand its product portfolio.
-
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
5/4/2023
Surface Oncology today reported financial results and corporate highlights for the first quarter 2023, as well as anticipated near-term milestones.
-
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
4/18/2023
Surface Oncology today announced the presentation of new preclinical data for SRF114, a fully human anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida.
-
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
3/9/2023
Surface Oncology today reported financial results and corporate highlights for the fourth quarter and full year 2022, as well as anticipated near-term corporate milestones.
-
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
2/28/2023
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a Novel Immuno-Oncology (IO) panel discussion at the Cowen 43rd Annual Health Care Conference taking place at the Marriott Copley Place in Boston, MA.
-
Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
2/2/2023
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the 2023 Guggenheim Oncology Days conference in New York City on Thursday, February 9, 2023, at 1:35 p.m. ET.
-
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
1/9/2023
Vaccinex, Inc. today announced that its licensee, Surface Oncology (NASDAQ: SURF, “Surface”) dosed the first patient in its Phase 1/2 clinical study investigating SRF114, an antibody discovered using Vaccinex’s ActivMAb.
-
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
1/5/2023
Surface Oncology today announced that the first patient has been dosed in its Phase 1/2 clinical study investigating SRF114, a potential best-in-class, fully human, afucosylated anti-CCR8 antibody, as a monotherapy in patients with advanced solid tumors.
-
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
11/7/2022
Surface Oncology today announced the presentation of two posters at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston.
-
Surface Oncology announced it is pausing the development of its CD39-targeted antibody SRF617 and cutting around 20% of its workforce to focus on its lead anti-IL-27 program SRF388.
-
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
11/2/2022
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, provided a corporate update and reported financial results for the third quarter of 2022.
-
VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
10/19/2022
VIB, Flanders’ leading life sciences institute, and Surface Oncology today announced jointly the publication of a study entitled, “Structural basis of activation and antagonism of receptor signaling mediated by interleukin-27: Cell Reports,” in Cell Reports, a leading scientific journal.
-
PD-L1 expression is not the static, “yes/no” predictor of tumor response for which researchers hoped. Surface Oncology, Immutep and Corbus are each taking a different approach to immuno-oncology.
-
Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting
9/14/2022
Surface Oncology today announced that the company will present new preclinical data on the role of IL-27 in therapy resistance at the 10th Annual Cytokines Meeting of the International Cytokine and Interferon Society (ICIS) being held September 20 – 23 at Big Island, Hawaii.
-
Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference
9/7/2022
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 10:15 a.m. ET.
-
Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase
8/24/2022
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the virtual Gilmartin Group Emerging Growth Company Showcase.
-
Surface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare Conference
8/1/2022
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a virtual panel discussion entitled, “IOs Wide Open - Opportunity and Challenges in Immuno-Oncology” at the 2022 Wedbush PacGrow Healthcare Conference.